Abstract
HIV Eradicating HIV in infected patients likely requires disrupting the reservoir of infected T cells in the gastrointestinal tract. One approach may be targeting cells expressing the integrin α4β7, which has been tested in simian immunodeficiency virus models and is an approved therapy for inflammatory bowel disease. Uzzan et al. studied a small cohort of HIV-infected individuals on antiretroviral therapy who began receiving an antibody against α4β7 as a treatment for their mild inflammatory bowel disease. Longitudinal colonoscopies revealed that the anti-α4β7 therapy disrupted local lymphoid aggregates. The treatment was well tolerated, but long-term effects on the HIV reservoir remain to be determined. Sci. Transl. Med. 10 , eaau4711 (2018).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
